Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study by Weber, Marianne et al.
University of Wollongong
Research Online
Faculty of Social Sciences - Papers Faculty of Social Sciences
2013
Sociodemographic and health-related predictors of
self-reported mammogram, faecal occult blood test









University of Wollongong, gsalkeld@uow.edu.au
Freddy Sitas
Cancer Council, NSW
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Weber, M. F., Cunich, M., Smith, D. P., Salkeld, G., Sitas, F. & O'Connell, D. (2013). Sociodemographic and health-related predictors
of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. BMC Public
Health, 13 (1), 429-1-429-13.
Sociodemographic and health-related predictors of self-reported
mammogram, faecal occult blood test and prostate specific antigen test use
in a large Australian study
Abstract
Background: While several studies have examined factors that influence the use of breast screening
mammography, faecal occult blood tests (FOBT) for bowel cancer screening and prostate specific antigen
(PSA) tests for prostate disease in Australia, research directly comparing the use of these tests is sparse. We
examined sociodemographic and health-related factors associated with the use of these tests in the previous
two years either alone or in combination. Methods. Cross-sectional analysis of self-reported questionnaire
data from 96,711 women and 82,648 men aged 50 or over in The 45 and Up Study in NSW (2006-2010).
Results: 5.9% of men had a FOBT alone, 44.9% had a PSA test alone, 18.7% had both tests, and 30.6% had
neither test. 3.2% of women had a FOBT alone, 56.0% had a mammogram alone, 16.2% had both and 24.7%
had neither test. Among men, age and socioeconomic factors were largely associated with having both FOBT
and PSA tests. PSA testing alone was largely associated with age, family history of prostate cancer, health
insurance status and visiting a doctor. Among women, age, use of hormone replacement therapy (HRT),
health insurance status, family history of breast cancer, being retired and not having a disability were
associated with both FOBT and mammograms. Mammography use alone was largely associated with age, use
of HRT and family history of breast cancer. FOBT use alone among men was associated with high income,
living in regional areas and being fully-retired and among women, being fully-retired or sick/disabled.
Conclusions: These results add to the literature on sociodemographic discrepancies related to cancer
screening uptake and highlight the fact that many people are being screened for one cancer when they could
be screened for two.
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Sociodemographic and health-related predictors
of self-reported mammogram, faecal occult blood
test and prostate specific antigen test use in a
large Australian study
Marianne F Weber1*, Michelle Cunich2, David P Smith1, Glenn Salkeld2, Freddy Sitas1 and Dianne O’Connell1,2,3,4
Abstract
Background: While several studies have examined factors that influence the use of breast screening mammography,
faecal occult blood tests (FOBT) for bowel cancer screening and prostate specific antigen (PSA) tests for prostate
disease in Australia, research directly comparing the use of these tests is sparse. We examined sociodemographic and
health-related factors associated with the use of these tests in the previous two years either alone or in combination.
Methods: Cross-sectional analysis of self-reported questionnaire data from 96,711 women and 82,648 men aged 50 or
over in The 45 and Up Study in NSW (2006–2010).
Results: 5.9% of men had a FOBT alone, 44.9% had a PSA test alone, 18.7% had both tests, and 30.6% had neither test.
3.2% of women had a FOBT alone, 56.0% had a mammogram alone, 16.2% had both and 24.7% had neither test.
Among men, age and socioeconomic factors were largely associated with having both FOBT and PSA tests. PSA testing
alone was largely associated with age, family history of prostate cancer, health insurance status and visiting a doctor.
Among women, age, use of hormone replacement therapy (HRT), health insurance status, family history of breast cancer,
being retired and not having a disability were associated with both FOBT and mammograms. Mammography use alone
was largely associated with age, use of HRT and family history of breast cancer. FOBT use alone among men was
associated with high income, living in regional areas and being fully-retired and among women, being fully-retired or
sick/disabled.
Conclusions: These results add to the literature on sociodemographic discrepancies related to cancer screening uptake
and highlight the fact that many people are being screened for one cancer when they could be screened for two.
Keywords: Cancer screening, Mammography, Faecal occult blood test, Prostate specific antigen test, Sociodemographic
characteristics, Socioeconomic status
Background
Prostate, breast and bowel cancer are the most commonly
diagnosed cancers in Australia and apart from lung cancer,
also account for the highest number of cancer-related
deaths [1]. There is clear evidence that early detection of
breast and bowel cancer via screening reduces the mortal-
ity associated with these diseases [2-4] and Australia has
national, government-funded screening programs for both
these cancers (breast since 1992 and bowel since 2006). In
contrast, although a mortality benefit has been found for
the early detection of prostate cancer using prostate spe-
cific antigen (PSA) testing [5], this form of screening is not
recommended by the Australian Government because the
harms outweigh the benefits [5,6]. However, PSA tests have
been subsidised by the Australian Government since 1989
and PSA testing for the early detection of prostate cancer
has received widespread media attention in recent years
[7]. Thus, PSA testing is effectively used as a de facto, albeit
disorganised, prostate cancer screening program [8].
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Among Australian women, participation in the breast
cancer screening program is around 55% (in the target
age group of 50–69 years) [9]. However, screening
mammograms are also commonly accessed through the
private sector on a user-pays basis and so the participa-
tion rate is more likely to be around 75% [10,11]. In
the bowel cancer screening program the participation
rate among those invited is around 38.4% (currently
only people turning 50, 55 and 65 are invited via a
mailed, faecal occult blood test; FOBT) [12]. FOBTs
are also available outside the program, but are not
widely used and so the overall participation rate in the
target age group remains similar to the program par-
ticipation rate [10]. The prevalence of PSA testing for
prostate cancer screening purposes in Australia is un-
known but estimated to be quite high. A nationally
representative study ten years ago found that 63% of
men aged >50 years had ever had a PSA test [13] and
this proportion is likely to have risen significantly since
then [8,14].
While there have been a few recent studies examining
factors that influence mammography, FOBT and PSA
test use in Australia [11,14-19], research comparing the
use of these different cancer screening tests is sparse.
Several studies in the USA have directly compared fac-
tors associated with being screened with more than one
of these test types [20-25] but only one study (limited
to men) has been reported from Australia [26]. These
studies have all found that many people are screened
for breast and prostate cancer but not for bowel cancer.
Although the test types are very different in nature
(FOBT is self-administered, mammography is an im-
aging technique done in a specialist clinic and PSA
tests are blood tests ordered by a general practitioner),
screening for one cancer type may potentially be a
“teachable moment” for screening for another cancer
type [27-29].
The objective of our study was to examine factors re-
lated to the use of FOBT, mammography and PSA tests
either alone or in combination. These factors included
individual-level socio-economic indicators as well as
demographic characteristics and health-related factors.
We used self-reported, cross-sectional data from The
45 and Up Study in New South Wales (NSW; Australia’s
most populous state) from participants aged 50 years
and over, who reported that they had never had cancer.
In a previous report, we found that 45 and Up Study
participants were more than twice as likely to have a
FOBT for bowel cancer if they had also had a mammo-
gram or a PSA test [30]. By investigating the use of a
range of cancer screening tests within the same popula-
tion, commonalities and discrepancies in the determi-




The 45 and Up Study is a population-based cohort study
of people aged 45 and over in NSW [31]. The cohort was
established with the aim of providing reliable evidence to
inform health policy to support Australia’s healthy ageing
population. Participants were randomly sampled from the
Medicare Australia database, Australia’s universal health
insurance system, which includes all citizens and perman-
ent residents of Australia, some temporary residents and
refugees. People aged 80 years and over and residents of
regional areas were oversampled by a factor of two. Partici-
pants completed a mailed self-administered questionnaire
and consent form. The participation rate was 18%, however
The 45 and Up study sample has excellent heterogeneity
and is reasonably representative of the NSW population;
has a response rate comparable to similar studies inter-
nationally and in Australia; and is among the most repre-
sentative large scale cohort studies in the world [32]. This
paper uses the baseline cross-sectional data from 232,056
people aged 50 and over who completed the questionnaire
between January 2006 and February 2010 (77% completed
the questionnaire in 2008). We chose the lower age limit
of 50 years because screening for bowel and breast cancer
is not recommended for people younger than 50 if they are
at normal risk, as is PSA testing for prostate cancer in
some Australian guidelines (e.g. the Urological Society of
Australia and New Zealand [33]).
Participants who reported ever having had cancer of
any type (except non-melanoma skin cancer) were ex-
cluded from analysis because many of these individuals
would have undergone more frequent surveillance than
those without cancer, n = 39,897 (17%; 20,502 men and
19,395 women). An additional 7,003 men and 5,797
women were excluded because they failed to provide
sufficient information on screening (6.6%). This left
82,648 men and 96,711 women for the main analyses
(n = 179,359).
The 45 and Up Study was approved by the University of
New South Wales Human Research Ethics Committee and
the Cancer Council New South Wales Ethics Committee.
Ascertainment of screening use
A self-reported history of bowel cancer screening was
ascertained from the question, “Have you ever been
screened for colorectal (bowel) cancer? If yes, please indi-
cate which test(s) you had”. We restricted our results to
FOBT use rather than colonoscopy or sigmoidoscopy be-
cause the National Bowel Cancer Screening Program
uses FOBT tests, and colonoscopy/sigmoidoscopy can be
used as a diagnostic test as well as a screening test. Breast
cancer screening was ascertained from the question
“Have you ever been for a breast screening mammo-
gram?”. A history of PSA testing was ascertained from
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the question, “Have you ever had a blood test ordered by
your doctor to check for prostate disease? (PSA test)”.
We were not able to distinguish men who had a PSA
test for prostate cancer screening from those who may
have had a PSA test to investigate disease. However, ap-
proximately two thirds of the PSA tests administered
Australia-wide in 2008 were for screening [34]. Add-
itionally, we excluded men with a history of prostate
cancer, which would have eliminated most men who
had PSA tests to monitor disease and we compared the
results from the full dataset with a sample of men that
excluded those who reported ever having an enlarged
prostate (16%). For all tests, respondents were asked to
indicate how long ago (in years) they had used each test
type and the analysis focussed on tests received in the
previous two years.
Ascertainment of socioeconomic, demographic and
health characteristics
All factors were obtained from the self-administered ques-
tionnaire and are listed in Tables 1 and 2. These included
age, education, annual household income from all sources
(note, the mean annual Australian income in 2009–2010
for people aged 45 years or older was $50,490 [35]), mar-
ried or living with a partner, language spoken at home,
country of birth, need help with daily tasks due to illness
or disability, psychological distress as measured by the
Kessler 10 scale [36], and ever used hormone replacement
therapy (HRT; women only). We also examined health in-
surance status, categorised as having 1) a health care con-
cession card (subsidised care for low income earners), 2) a
Department of Veterans’ Affairs card (subsidised care for
current and past members of the Australian defence force
and their spouses), 3) private health insurance without ex-
tras (covers ambulance and hospital services only), 4) pri-
vate health insurance with extras (i.e. covers dental
treatments and specialist services such as physiotherapy),
or 5) no concession card or health Insurance. It should be
noted, however, that all Australians have free universal
access to hospital treatment in public hospitals and
subsidised out-of-hospital medical treatment and medica-
tions. Those with concession cards receive larger subsidies
and those with private health insurance are covered (to
varying degrees, depending on the policy) for treatment in
private hospitals.
The questionnaire also collected information about re-
cent treatment for a number of medical conditions
(heart attack, other heart disease, high blood pressure,
high blood cholesterol, blood clotting problems, asthma,
osteoarthritis, thyroid problems, osteoporosis/low bone
density, depression and/or anxiety) and in the absence of
a single question about visits to a doctor, these items
were combined to get a partial measure of contact with
the health system for reasons other than screening.
Analyses
We examined the proportion of men who reported hav-
ing a PSA test alone, a FOBT alone, neither test, or both
tests within the past 2 years by socioeconomic, demo-
graphic and health characteristics. Similarly, we com-
pared the proportion of women who reported having a
mammogram alone, a FOBT alone, neither test or both
tests within the last 2 years by socioeconomic, demo-
graphic and health characteristics.
Odds ratios and 95% confidence intervals (CI) corre-
sponding to receiving each test type, both tests, or nei-
ther test for each socioeconomic, demographic and
health factor were estimated using multinomial logistic
regression with a generalised logit link function. Each
model included all the factors listed in Table 1 for men
and Table 2 for women. Missing values for each covari-
ate were included in the models as a separate term to
prevent loss of information (data not shown). We also
analysed the data after excluding participants with miss-
ing values for any covariate.
Results
Descriptive statistics
Of the 82,648 men included in the main analyses, 5.9%
reported having an FOBT alone, 44.9% reported having a
PSA test alone, 18.7% reported having both tests, and
30.6% reported having neither test within the previous
2 years. Of the 96,711 women included in the main
analyses, 3.2% reported having an FOBT alone, 56.0%
reported having a mammogram alone, 16.2% reported
having both tests, and 24.7% reported having neither
test within the previous 2 years. The prevalence of test
use weighted for age and region of residence among
men in our sample (according to the NSW population
in 2006 [37]), was 23.1% for FOBT and 62.3% for PSA
tests. Among women, the weighted prevalence was
17.7% for FOBT and 68.2% for mammography. Table 1
shows the distribution of each socioeconomic, demo-
graphic and health-related characteristic by each test
combination (FOBT, PSA test, both tests, or neither test)
for men and Table 2 shows the distribution of each socio-
economic, demographic and health-related characteristic
by each test combination (FOBT, mammogram both
tests, or neither test) for women.
Multinomial logistic regression
Figure 1 shows the odds ratios for receipt of FOBT
alone, PSA test alone, or both tests compared to men
who reported having neither test in the previous 2 years.
The model included all the factors listed in Table 1 and
all factors were significantly associated with screening
test use (p < .0001). Figure 2 shows the odds ratios for
the receipt of FOBT alone, mammography alone, or both
tests compared to women who had neither test in the
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Table 1 Characteristics of men in the 45 and Up study who reported ever having a faecal occult blood test (FOBT),
prostate specific antigen (PSA) test, both tests, or neither test in the previous 2 years
n (%)1 % FOBT only % PSA test only % Both tests % Neither test
Total n 82,648 (100) 5.9 44.9 18.7 30.6
Age
50-59 32102 (38.8) 7.1 40.3 16.7 35.9
60-69 27572 (33.4) 5.6 47.6 24.0 22.8
70+ 22974 (27.8) 4.8 47.7 14.9 32.5
Family history of cancer
Bowel 9449 (11.4) 6.4 46.3 17.6 29.7
Prostate 7173 (8.7) 4.5 50.4 23.0 22.1
Bowel and Prostate 1421 (1.7) 5.4 49.6 20.7 24.3
Other Cancer 15816 (19.1) 6.4 44.3 19.6 29.7
None 48789 (59.0) 5.9 43.8 17.8 32.4
Place of residence*
Major City 38086 (46.1) 5.2 46.0 16.4 32.4
Inner Region 28464 (34.4) 6.3 44.5 20.5 28.7
Outer Region 14498 (17.5) 7.2 42.3 21.4 29.2
Remote or Very Remote 1535 (1.9) 4.7 46.5 14.9 33.9
Highest qualification
No school certificate or other qualification 8876 (10.7) 4.7 45.7 13.8 35.8
School or intermediate certificate 12535 (15.2) 5.3 47.4 17.5 29.9
Higher school or leaving certificate 7932 (9.6) 5.6 44.3 16.6 33.6
Trade, apprenticeship, certificate or diploma 31105 (37.6) 5.9 45.7 19.4 29.0
University degree or higher 20849 (25.2) 7.1 42.0 21.4 29.5
Employment status
Full time work 22345 (27.0) 6.7 42.8 17.5 33.0
Part time work 5873 (7.1) 6.5 44.3 20.0 29.3
Self employed 11526 (14.0) 5.9 45.1 18.1 30.8
Partially retired 3935 (4.8) 5.9 46.1 23.4 24.6
Fully retired 32971 (39.9) 5.4 46.5 20.2 27.9
Unemployed 1529 (1.9) 6.3 37.8 9.2 46.6
Unpaid work 646 (0.8) 6.2 45.2 15.2 33.4
Looking after home/family 394 (0.5) 5.8 41.9 11.7 40.6
Sick/disabled 2282 (2.8) 4.4 44.0 11.0 40.7
Other 674 (0.8) 3.9 45.6 15.7 34.9
Income ($AUD)†
Less than 5,000 982 (1.2) 4.1 43.0 8.3 44.7
5,000-9,000 2953 (3.6) 5.2 43.8 9.2 41.8
10,000-19,000 11543 (14.0) 5.0 45.4 14.1 35.5
20,000-29,000 8545 (10.3) 5.8 46.2 18.4 29.5
30,000-39,000 7231 (8.8) 6.4 44.8 21.5 27.4
40,000-49,000 6745 (8.2) 6.0 44.2 21.7 28.2
50,000-69,000 9695 (11.7) 6.4 44.6 21.9 27.2
70,000 or more 22676 (27.4) 6.9 44.1 20.7 28.3
Prefer not to answer 10331 (12.5) 4.8 46.0 17.4 31.9
Health insurance status
Health care concession card 14022 (17.0) 5.0 43.5 14.1 37.5
Department of Veterans’ Affairs card 1832 (2.2) 5.1 42.3 12.1 40.6
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previous 2 years. The model included all the factors
listed in Table 2 and all factors were significantly associ-
ated with screening test use (p < .0001). In order to sum-
marise the results presented in the figures we either
highlight the factors with odds ratios (OR) of ~2 or
more (or ~0.5 or less) or factors having the largest inde-
pendent effects.
Overall, the factors with estimated ORs of ~2 or more
(or ~0.5 or less) for the receipt of both FOBT and PSA
tests among men were age (60–69 vs 50–59 years; OR =
1.94, 95% CI 1.83-2.06), annual household income less than
$9,000 (vs. $70,000+; OR = 0.40, 95% CI 0.35-0.47) or
$5,000 (OR = 0.34, 95% CI 0.26-0.43), being fully-retired
(vs. full-time employment; OR = 1.93, 95% CI 1.79-2.07)
and having private health insurance (OR = 2.10, 95% CI
1.96-2.25). For having PSA tests alone, the factors with the
largest independent effects were age (60–69 vs 50–59
years; OR = 1.80, 95% CI 1.72-1.89), having a family history
of prostate cancer (OR = 1.64, 95% CI 1.54-1.75), having
private health insurance (OR = 1.60, 95% CI 1.52-1.68) and
being treated by a doctor in the past month (OR = 1.49,
95% CI 1.44-1.55). For use of FOBTs alone among men,
the factors associated with the largest independent effects
were income less than $5,000 (vs. $70,000+; OR = 0.52,
95% CI 0.37-0.73), living in outer regional areas (vs. major
city; OR = 1.55, 95% CI 1.42-1.69), and being fully-retired
(vs. full-time employment; OR = 1.53, 95% CI 1.37-1.71.
Among women, the factors with ORs of ~2 or more
(or ~0.5 or less) for the receipt of both FOBT and mam-
mograms were age (70+ vs 50–59 years; OR = 0.12, 95%
CI 0.11-0.13), use of HRT (OR = 2.41, 95% CI 2.29-2.52),
health insurance status: private (OR = 2.38, 95% CI 2.22-
2.56) or private plus extras (OR = 2.19, 95% CI 2.02-
2.39), family history of breast cancer (OR = 2.05, 95% CI
1.89-2.21), being partially retired (vs. full-time employ-
ment; OR = 2.03, 95% CI 1.76-2.35) or fully retired
(OR = 2.00, 95% CI 1.84-2.19), and needing help with daily
tasks (OR = 0.46, 95% CI 0.41-0.52). For use of mammog-
raphy alone, the factors with estimated ORs of ~2 or more
(or ~0.5 or less) were age (70+ vs 50–59 years; OR = 0.16,
Table 1 Characteristics of men in the 45 and Up study who reported ever having a faecal occult blood test (FOBT),
prostate specific antigen (PSA) test, both tests, or neither test in the previous 2 years (Continued)
Private health insurance without extras 41033 (49.7) 6.2 46.6 22.0 25.3
Private health insurance with extras 12142 (14.7) 6.0 46.1 20.2 27.6
No concession card or health Insurance 12141 (14.7) 6.4 40.3 12.8 40.5
Married or living with a partner
No 15150 (18.3) 5.7 40.9 13.4 40.0
Yes 66802 (80.8) 6.0 45.7 19.9 28.5
Non-English language spoken at home
No 73979 (89.5) 6.1 44.8 19.7 29.3
Yes 8667 (10.5) 4.2 44.9 9.5 41.4
Been treated by a doctor in the past month§
No 38102 (46.1) 6.5 41.5 18.5 33.5
Yes 35939 (43.5) 5.4 48.4 19.6 26.7
Country of birth
Australia 59373 (71.8) 6.2 45.5 20.3 28.1
Other English speaking country 11214 (13.6) 6.4 41.2 17.8 34.6
Non-English speaking country 11222 (13.6) 4.3 45.4 11.0 39.2
Need help with daily tasks due to illness or disability
No 76255 (92.3) 6.1 44.8 19.5 30.0
Yes 3761 (4.6) 4.3 43.8 11.9 40.0
Psychological distress Level
Well 67398 (81.6) 6.1 44.7 19.7 29.5
Mild 3994 (4.8) 6.0 43.9 16.3 33.9
Moderate 1294 (1.6) 5.0 45.4 14.4 35.2
Severe 1243 (1.5) 5.2 41.8 12.6 40.5
1 Missing data for each covariate has been omitted for the sake of brevity.
* Using the mean Accessibility/Remoteness Index of Australia (ARIA+).
† Pre-tax annual household income from all sources.
§Treated for heart attack, other heart disease, high blood pressure, high blood cholesterol, blood clotting problems, asthma, osteoarthritis, thyroid problems,
osteoporosis/low bone density, depression, or anxiety.
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Table 2 Characteristics of women in the 45 and Up study who reported ever having a faecal occult blood test (FOBT),
mammogram, both tests, or neither test in the previous 2 years
Total n (%)1 % FOBT only % Mammogram only % Both tests % Neither test
Total n 96711 (100) 3.2 56.0 16.2 24.7
Age
50-59 42646 (44.1) 2.5 62.5 17.1 18.0
60-69 30538 (31.6) 2.0 65.4 21.7 11.0
70+ 23527 (24.3) 5.9 32.0 7.3 54.7
Family history of cancer
Bowel 11836 (12.2) 4.1 54.1 16.8 25.0
Breast 9937 (10.3) 2.3 62.5 18.1 17.1
Bowel and Breast 2077 (2.2) 3.0 58.7 17.4 20.9
Other Cancer 20273 (21.0) 2.9 57.1 17.2 22.8
None 52588 (54.4) 3.2 54.7 15.2 27.0
Hormone replacement therapy use
Ever 40641 (42.0) 2.8 61.5 20.0 15.7
Never 53905 (55.7) 3.4 52.2 13.6 30.8
Place of residence*
Major City 42402 (43.8) 2.9 55.8 14.3 27.0
Inner Region 34676 (35.9) 3.3 56.1 17.2 23.5
Outer Region 17697 (18.3) 3.3 55.9 18.8 22.0
Remote or Very Remote 1853 (1.9) 3.1 60.4 15.1 21.4
Highest qualification
No school certificate or other qualification 12720 (13.2) 3.4 52.1 10.5 34.0
School or intermediate certificate 28347 (29.3) 2.9 57.0 15.7 24.5
Higher school or leaving certificate 9297 (9.6) 2.9 55.9 13.9 27.3
Trade, apprenticeship, certificate or diploma 24918 (25.8) 3.5 55.9 18.2 22.4
University degree or higher 19928 (20.6) 3.1 57.7 19.5 19.7
Employment status
Full time work 16829 (17.4) 2.0 64.0 15.6 18.5
Part time work 16599 (17.2) 2.5 63.8 18.7 15.0
Self employed 6559 (6.8) 2.6 60.7 17.9 18.8
Partially retired 3030 (3.1) 2.9 59.3 22.1 15.8
Fully retired 39603 (41.0) 4.1 48.2 15.8 31.8
Unemployed 2088 (2.2) 3.0 54.6 9.4 33.1
Unpaid work 1952 (2.0) 2.9 59.8 17.0 20.3
Looking after home/family 5914 (6.1) 2.7 58.0 14.7 24.6
Sick/disabled 2004 (2.1) 3.8 54.9 9.2 32.0
Other 1245 (1.3) 2.8 56.0 12.4 28.8
Income ($AUD)†
Less than 5,000 1878 (1.9) 3.0 52.6 10.8 33.7
5,000-9,000 4423 (4.6) 3.4 50.1 9.6 37.0
10,000-19,000 14983 (15.5) 4.3 48.1 12.1 35.6
20,000-29,000 9511 (9.8) 3.7 54.3 17.2 24.9
30,000-39,000 7593 (7.9) 3.3 58.6 18.5 19.7
40,000-49,000 6565 (6.8) 2.9 58.8 19.1 19.3
50,000-69,000 9214 (9.5) 2.7 60.4 19.3 17.6
70,000 or more 17348 (17.9) 2.3 62.5 19.6 15.7
Prefer not to answer 20589 (21.3) 3.1 57.1 16.0 23.8
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95% CI 0.15-0.17), use of HRT (OR = 2.08, 95% CI 2.01-
2.17), and family history of breast cancer (OR = 1.99, 95%
CI 1.87-2.12). For use of FOBTs alone among women the
factor with the largest independent effect was employment
status: fully retired (OR = 1.93, 95% CI 1.63-2.29) or being
sick/disabled (OR = 1.93, 95% CI 1.44-2.58) compared to
women in full-time employment.
The estimated odds ratios changed less than 10% when
we compared the full dataset with a complete case
dataset, and also when comparing the full dataset with a
sample that excluded men who had ever had an enlarged
prostate.
Discussion
The 45 and Up Study is the largest population-based co-
hort study in Australia and the results presented here,
using uniform outcome measures, suggest that there are
different factors related to cancer screening depending
on the type of test. Specifically, among women, having
mammography alone was associated most strongly with
age and well known health-related factors such as HRT
use and family history of breast cancer, whereas having a
FOBT alone was associated most strongly with being re-
tired or sick/disabled. Among men, having a PSA test
alone was associated most strongly with age, family his-
tory of prostate cancer, having private health insurance,
and being treated by a doctor in the past month,
whereas having a FOBT alone was associated most
strongly with higher income, living in outer regional
areas and being retired. The factors included in our ana-
lysis were factors that have been found to be associated
with cancer screening in the past [11,14-19], and indeed,
all these factors were significantly related to cancer
screening in our study. Only one other study has directly
Table 2 Characteristics of women in the 45 and Up study who reported ever having a faecal occult blood test (FOBT),
mammogram, both tests, or neither test in the previous 2 years (Continued)
Health insurance status
Health care concession card 18482 (19.1) 3.7 49.0 11.2 36.0
Department of Veterans’ Affairs card 1095 (1.1) 4.8 32.8 6.6 55.9
Private health insurance without extras 47793 (49.4) 2.9 59.8 19.2 18.2
Private health insurance with extras 14187 (14.7) 3.2 56.2 18.0 22.6
No concession card or health Insurance 13428 (13.9) 3.1 54.8 12.1 30.1
Married or living with a partner
No 28821 (29.8) 4.0 47.3 11.8 36.9
Yes 67599 (69.9) 2.8 59.7 18.0 19.5
Non-english language spoken at home
No 88039 (91.0) 3.2 55.9 16.9 24.0
Yes 8671 (9.0) 2.5 56.7 8.6 32.2
Country of birth
Australia 73198 (75.7) 3.2 56.2 17.2 23.4
Other English speaking country 11848 (12.3) 3.4 55.0 16.6 25.0
Non-English speaking country 10720 (11.1) 2.8 56.0 9.4 31.8
Been treated by a doctor in the past month§
No 39055 (40.4) 2.7 58.6 17.0 21.8
Yes 49328 (51.0) 3.6 53.7 16.1 26.6
Need help with daily tasks due to illness or disability
No 88048 (91.0) 3.1 57.3 16.9 22.8
Yes 5247 (5.4) 4.1 39.0 8.1 48.7
Psychological distress Level
Well 74194 (76.7) 3.1 57.2 17.6 22.1
Mild 5366 (5.6) 3.2 57.9 14.1 24.8
Moderate 1706 (1.8) 2.9 53.8 13.0 30.3
Severe 1679 (1.7) 2.9 54.6 10.3 32.3
1 Missing data for each covariate has been omitted for the sake of brevity.
* Using the mean Accessibility/Remoteness Index of Australia (ARIA+).
† Pre-tax annual household income from all sources.
§Treated for heart attack, other heart disease, high blood pressure, high blood cholesterol, blood clotting problems, asthma, osteoarthritis, thyroid problems,
osteoporosis/low bone density, depression, or anxiety.
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Figure 1 Odds ratios and 95% confidence intervals for receipt of faecal occult blood test (FOBT) alone, prostate specific antigen (PSA)
test alone, or both tests for men in the previous 2 years compared to those who reported having neither test in the 45 and Up study.
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Figure 2 Odds ratios and 95% confidence intervals for receipt of faecal occult blood test (FOBT) alone, mammogram alone, or both
tests for women in the previous 2 years compared to those who reported having neither test in the 45 and Up study.
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compared cancer screening modalities in Australia and
that study, restricted to men, also found that PSA testing
was more common than bowel screening and that having
private health insurance, living with a partner and being
white and older were associated with any screening [26].
In Australia, even though national guidelines have ad-
vocated bowel cancer screening since 1999 for asymp-
tomatic people from the age of 50 years, a freely
available program for bowel cancer screening has only
been available to people turning 50 and 55 from 2006
and those turning 50, 55 and 65 from 2008. Prior to
2006, FOBTs were available from 1982 via the Rotary
program “Bowelscan” which is run annually throughout
most states of Australia at a nominal cost to the individ-
ual. In contrast, free population screening for breast can-
cer has been offered to women aged 50–69 since 1992
and has been widely advocated. PSA testing is not cur-
rently recommended as a population-based screening
tool for prostate cancer, but is subsidised by the govern-
ment, has had considerable media attention and is an
easy test to administer. Thus, given the circumstances
surrounding access to each of these tests in Australia, it
is not surprising that FOBT use overall was lower than
that for mammography and PSA test use and that having
each test is associated with different socioeconomic and
demographic factors.
A number of studies have proposed that screening for
one cancer type is a potential “teachable moment” for
screening for another cancer type, especially given that
those having mammograms or PSA tests may be a group
that are aware of, and interested in, the benefits of the
early detection of cancer [27-29]. The breast cancer
screening program in Australia is relatively successful (in
terms of uptake and reducing breast cancer mortality
[38]), and even though the evidence in favour of PSA
testing as a screening tool for prostate cancer remains
controversial, many men are being tested regardless. We
observed in the 45 and Up Study that 72% of women
had a mammogram in the previous 2 years and 63% of
men had a PSA test. This suggests that bowel screening
rates have the potential to increase markedly from the
22% reported here if promoted through existing health
networks. Indeed, in a previous report, we found that 45
and Up Study participants were more than twice as
likely to have a FOBT if they had also had a mammo-
gram or a PSA test [30]. Currently, the cancer screening
programs in Australia are not integrated. However, deci-
sion aids that provide information regarding the harms
and benefits of each test side by side may increase the
uptake of FOBT – especially for men, since positive
messages about screening seem to be deeply ingrained
for PSA testing [39].
Socioeconomic factors, especially income, had the
strongest effects on being screened for two cancer types.
Specifically, those reporting low income and to a lesser
degree, education, were less likely to have had two tests.
The national monitoring reports of the screening pro-
grams, which are based on area-level socioeconomic
classification, report lower participation for low socio-
economic sub-groups in the bowel cancer screening pro-
gram but less so in the breast screening program
[9,12,15]. Factors associated with PSA test use have not
been widely explored, but one study in Australia found
that socioeconomic factors were not strongly associated
with PSA test use [18]. We found that low income
groups were less likely to have had a FOBT alone, but
not a mammogram alone and to a lesser degree, PSA
tests alone. Educational status was related to use of
FOBT in both men and women, as well as the combined
use of FOBT and PSA test/mammography, but was not
related to PSA test or mammogram use alone. This find-
ing suggests that low levels of education were specifically
related to low levels of bowel cancer screening. Previous
studies have demonstrated that social inequality is a fac-
tor for the formation of attitudes towards screening
[40,41]. For example, one study has shown that people
with low socioeconomic status (SES) viewed bowel can-
cer screening as less beneficial and more frightening
than those with higher SES [41]. Thus, when cost and
access are not obvious barriers to cancer screening, en-
couraging people in low socioeconomic groups to par-
ticipate in the bowel cancer screening program may
require targeted promotional campaigns aimed at ad-
dressing negative attitudes towards cancer screening.
Interestingly, living in regional and remote areas was
not a barrier to cancer screening in our study. Indeed,
people in regional and remote areas were more likely to
be screened for bowel and breast cancer than those liv-
ing in a major city (there was no variation in the use of
PSA tests alone by place of residence). Australia is a vast
country and there are health inequalities across geo-
graphic locations, especially in areas of geographic isola-
tion, and a number of reports have demonstrated that
people in regional areas have poorer survival from can-
cer than those in major cities [42,43]. However, our
study is in concordance with others showing that both
mammogram and FOBT uptake via the national pro-
grams is higher in rural areas than in the city [12,15,44].
This suggests that geographic differences in cancer sur-
vival are possibly due to differences in access to treat-
ments and/or to socioeconomic discrepancies in survival
rather than to delayed diagnosis. Higher levels of cancer
screening in regional areas could possibly be due to a
greater level of community strength and engagement in
regional areas, leading to a greater community aware-
ness of cancer screening. For example, the Breast
Screening Program in NSW is largely operated out of a
mobile van that travels from town to town. This event is
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likely to be much more salient in a small town with a
single central shopping centre than in the urban sprawl
of the city, and indeed, in some Australian cities the pro-
gram is run entirely from clinics. Thus, the presence of
the mobile van may facilitate a level of awareness of the
program in rural and regional areas that may be lacking
in urban areas. Moreover, limited research has shown
that community strength is greater in rural Australia
than in the cities [45], and higher levels of social integra-
tion are positively related to cancer screening uptake
[46]. It is also possible that, in the case of bowel screen-
ing, people living in major cities are more likely to have
a colonoscopy than those in regional areas where acces-
sibility to colonoscopy clinics is more limited (although
not explored here).
Those who were retired, in part-time work or in unpaid
work were more likely to be screened than those in
fulltime work. This result is consistent with studies
showing that often people state that lack of time is a rea-
son for not participating in bowel screening [47,48]. That
is, those in fulltime work have less free time to be
screened. There was very little variation in screening up-
take among those who reported their employment status
as sick/disabled or unemployed compared to those in
fulltime work. However, both men and women who
reported needing help with daily tasks because of illness
or disability had low levels of screening test use. This
may be explained in terms of access issues and the ability
to get to a mammography clinic/doctor, or to perform a
FOBT at home. Alternatively, it may be the case that
these participants have more immediate health problems,
possibly a shorter life expectancy, and have therefore
made a reasonable decision that the small long-term ben-
efits of screening are not relevant for them. However we
also found that those who reported being treated by a
doctor for a major illness in the past month were signifi-
cantly more likely to have been screened than those who
had not been treated in the past month. This finding
is in line with previous reports showing that routine
visits to a doctor are associated with cancer screening
[29,40,49-51], and highlights the important role for gen-
eral practitioners in cancer testing, even though they
may not be responsible for administering the tests (i.e. in
the case of FOBT and mammography) [48,52-56].
This study had a number of limitations. Firstly, cancer
screening history was derived from self-report, however a
meta-analysis of validation studies on self-reported can-
cer screening use in the USA found that self-reported
versus documented history of screening had reasonably
high sensitivity (0.78 for FOBT, 0.95 for mammography,
0.71 for PSA) and specificity (0.90 for FOBT, 0.61 for
mammography, 0.73 for PSA) [57]. Secondly, we were
not able to identify participants who had a PSA test for
monitoring, rather than screening purposes, however by
excluding men who had ever had prostate cancer we
were able to eliminate most of these. Additionally, when
we excluded men who had ever had an enlarged prostate
from the sample, the observed odds ratios changed by
less than 10%. Finally, our results may not be representa-
tive of the general population because cohort study par-
ticipants tend to be healthier and more health conscious
than non-participants [58] and the participation rate was
only 18%. However, like most long-term cohort studies,
The 45 and Up Study is designed to provide sufficient
heterogeneity for valid comparisons within the cohort,
rather than specific estimates of prevalence of exposure
in the population [59]. Previous reports have demon-
strated that The 45 and Up Study cohort has sufficient
spread in the responses to questionnaire items for in-
ternal comparisons [31] and that exposure-outcome rela-
tionships are very similar to those from a survey of a
representative sample from the same population [32]. Po-
tential bias resulting from the “healthy cohort” effect, if it
is present, generally leads to more conservative results
due to reduced representation of population groups who
have more extreme health behaviours, such as those who
are mentally or physically ill or marginalised for some
other reason. Hence, the associations observed between
sociodemographic characteristics and screening may be
somewhat closer to the null than might be seen among
comparisons of community members who do not tend to
participate in studies of this type. Caution must also be
exercised when interpreting any negative results.
Conclusions
Overall, this paper adds to the empirical literature on
economic and social discrepancies related to cancer
screening uptake. Most importantly, our results highlight
the fact that many people are being screened for one
cancer type when they could be screened for two. Strat-
egies aimed at using one test as a ‘teachable moment’ for
promoting another test may help close the gap in socio-
demographic discrepancies in cancer screening to a cer-
tain extent.
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